Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis

详细信息    查看全文

• 作者：Haiming Yu ; Junlan Yang ; Shunchang Jiao ; Ying Li…
• 关键词：Breast cancer ; Disease ; free survival ; Overall survival ; Cytotoxic T lymphocyte antigen 4 ; CTLA ; 4
• 刊名：Cancer Immunology, Immunotherapy
• 出版年：2015
• 出版时间：July 2015
• 年：2015
• 卷：64
• 期：7
• 页码：853-860
• 全文大小：657 KB
• 参考文献：1.Emens LA (2012) Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther 12:1597-611. doi:10.-586/?era.-2.-47 PubMed Central PubMed View Article
  2.Koch MA, Thomas KR, Perdue NR, Smigiel KS, Srivastava S, Campbell DJ (2012) T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2. Immunity 37:501-10. doi:10.-016/?j.?immuni.-012.-5.-31 PubMed Central PubMed View Article
  3.Yu HM, Yang JL, Jiao SC, Wang JD, Li Y (2014) TGF-β1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer. J Huazhong Univ Sci Technol Med Sci 34:51-8. doi:10.-007/?s11596-014-1231-2 PubMed View Article
  4.Grosso JF, Jure-Kunkel MN (2013) CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immunol 13:5
  5.Pérez-García A, Osca G, Bosch-Vizcaya A et al (2013) Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription. Hum Immunol 74:1219-224. doi:10.-016/?j.?humimm.-013.-5.-12 PubMed View Article
  6.Greenwald RJ, Latchman YE, Sharpe AH (2002) Negative co-receptors on lymphocytes. Curr Opin Immunol 14:391-96PubMed View Article
  7.Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565-94PubMed View Article
  8.Ward FJ, Dahal LN, Wijesekera SK, Abdul-Jawad SK, Kaewarpai T, Xu H, Vickers MA, Barker RN (2013) The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol 43:1274-285. doi:10.-002/?eji.-01242529 PubMed View Article
  9.Sigal LH (2012) Basic science for the clinician 55: CTLA-4. J Clin Rheumatol 18:155-58. doi:10.-097/?RHU.-b013e31824ea103-/span> PubMed View Article
  10.Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao W, Deng B, Sun J, Shao Q, Qu X (2010) New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets 10:728-36PubMed View Article
  11.Contardi E, Palmisano GL, Tazzari PL et al (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538-50PubMed View Article
  12.Jaberipour M, Habibagahi M, Hosseini A, Habibabad SR, Talei A, Ghaderi A (2010) Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res 16:547-51. doi:10.-007/?s12253-010-9256-8 PubMed View Article
  13.Erfani N, Razmkhah M, Ghaderi A (2010) Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer. Cancer Invest 28:828-32. doi:10.-109/-735790100363093- PubMed View Article
  14.Cimino PJ Jr, Perrin RJ (2014) Mammaglobin-A immunohistochemistry in primary central nervous system neoplasms and intracranial metastatic breast carcinoma. Appl Immunohistochem Mol Morphol 22:442-48. doi:10.-097/?PAI.-b013e318294ca46-/span> PubMed View Article
  15.Huurman VA, Unger WW, Koeleman BP, Oaks MK, Chandraker AK, Terpstra OT, Roep BO (2007) Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y. Clin Exp Immunol 150:487-93PubMed Central PubMed View Article
  16.Laurent S, Queirolo P, Boero S et al (2013) The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med 11:108. doi:10.-186/-479-5876-11-108 PubMed Central PubMed View Article
  17.Simpson TR, Li F, Montalvo-Ortiz W et al (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695-710. doi:10.-084/?jem.-0130579 PubMed Central PubMed View Article
  18.Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL (2013) Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210:1685-693. doi:10.-084/?jem.-0130573 PubMed Central PubMed View Article
  19.Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1:32-2. doi:10.-158/-326-6066.?CIR-13-0013 PubMed View Article
  20.Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-23. doi:10.-056/?NEJMoa1003466 PubMed Central PubMed View Article
  21.Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S (2014) Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets The
• 作者单位：Haiming Yu (1)
  Junlan Yang (1)
  Shunchang Jiao (1)
  Ying Li (1)
  Wei Zhang (2)
  Jiandong Wang (3)
  
  1. Department of Medical Oncology, General Hospital of Chinese People’s Liberation Army, No. 28, Fuxing Road, Haidian District, Beijing, 100853, People’s Republic of China
  2. Department of Pathology, 401 Hospital of People’s Liberation Army, Qingdao, People’s Republic of China
  3. Department of General Surgery, General Hospital of Chinese People’s Liberation Army, Beijing, People’s Republic of China
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Immunology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0851

文摘

To examine the relationship between cytotoxic T lymphocyte antigen 4 (CTLA-4) expression and breast cancer prognosis, CTLA-4 expression was immunohistochemically detected in paraffin-embedded specimens of primary tumors from 130 patients with breast cancer who had a mean follow-up period of 112?months. CTLA-4 expressed in cytoplasm of breast cancer cells and in cytoplasm and cell membranes of interstitial lymphocytes. Univariate analysis (log-rank) associated higher density of interstitial CTLA-4+ lymphocytes with longer DFS and OS, but higher tumor CTLA-4 expression with shorter OS. After controlling for age, clinical stage, Scarff-Bloom-Richardson grade, tumor thrombus, ER, PR, HER2 and Ki-67, multivariate analysis (Cox) showed that density of interstitial CTLA-4+ lymphocytes independently predicted longer DFS (HR 0.315, P?=?0.002) and OS (HR 0.313, P?=?0.005), whereas tumor CTLA-4 expression independently predicted shorter DFS (HR 2.176, P?=?0.029) and OS (HR 2.820, P?=?0.007), i.e., patients with high CTLA-4+ lymphocyte density and CTLA-4low tumor cells had the best prognoses. These results indicated that CTLA-4 expression in lymphocytes was associated with better prognosis, but that in tumor cells was associated with worse prognosis. Patients-CTLA-4 profiles might thus be used to predict the benefits and toxicity of CTLA-4 blockade.